Inhibition of PARP1 in BRCA1- or BRCA2-deficient cancer cells leads to synthetic lethality, because these mutant cells rely on PARP1 for blocking cellular accumulation of catastrophic DSBs31, 32, 33, 34. This evidence concerns the gene BRCA2 and cancer.